worldwid
viral
respiratori
tract
infect
vrti
respons
substanti
morbid
mortal
unit
kingdom
uk
pneumonia
influenza
rank
fourth
sixth
underli
caus
death
femal
male
respect
similarli
unit
state
america
pneumonia
influenza
rank
sixth
caus
hospit
among
medicar
beneficiari
howev
like
underestim
true
burden
vrti
unrecogn
infect
may
lead
complic
respiratori
cardiovascular
neurolog
hospit
death
clinic
present
vrti
similar
laboratori
confirm
import
determin
pathogen
respons
infect
although
viral
cultur
remain
gold
standard
diagnosi
practic
viru
isol
replac
nucleic
acid
amplif
test
naat
refer
laboratori
given
increas
sensit
specif
breadth
reduc
turnaround
time
tat
pathogen
detect
contrast
pointofcar
poc
test
nearpati
test
nonmolecular
molecularbas
increasingli
use
improv
patient
outcom
provid
faster
tat
poc
test
defin
test
patient
sampl
perform
surgeri
clinic
near
time
consult
poc
test
also
use
laboratori
environ
provid
rapid
test
tradit
batch
eg
multiplex
naat
slower
eg
viru
isol
laboratori
test
poc
devic
especi
nonmolecularbas
assay
advantag
requir
special
laboratori
equip
expertis
oper
make
suitabl
near
patient
deploy
provid
rapid
result
realtim
translat
improv
clinic
decisionmak
qualiti
care
manag
vrti
poc
test
facilit
prescript
antivir
guid
infect
control
obviat
unnecessari
investig
therapi
world
health
organ
develop
assur
afford
sensit
specif
userfriendli
rapid
robust
equipmentfre
deliver
criteria
paradigm
poc
test
devic
poc
test
base
later
flow
immunochromatographi
lfic
remain
domin
method
despit
obviou
limit
limit
sensit
inabl
multiplex
although
lab
chip
technolog
yet
fulli
translat
clinic
practic
like
becom
common
futur
review
aim
explor
differ
poc
test
current
avail
diagnos
vrti
discuss
advantag
limit
poc
test
provid
insight
futur
poc
test
main
limit
nonmolecularbas
poc
test
reduc
sensit
specif
compar
naat
well
expens
limit
valid
shelflif
year
reagent
howev
limit
necessarili
preclud
use
detect
manag
vrti
furthermor
analyt
sensit
specif
poc
test
continu
improv
compar
current
naat
newer
method
technolog
detect
nucleic
acid
incorpor
poc
test
natur
poc
test
also
design
high
throughput
applic
capac
test
multipl
specimen
concurr
addit
earlier
gener
poc
test
use
diagnosi
vrti
detect
one
pathogen
influenza
respiratori
syncyti
viru
rsv
howev
newer
nucleicaciddetectionbas
nonnucleicaciddetectionbas
multiplex
poc
test
detect
multipl
respiratori
virus
develop
use
beadbas
arraybas
technolog
avail
pathogenspecif
antivir
therapi
anticip
increas
requir
identifi
etiolog
agent
vrti
tradit
immunochromatograph
ridt
may
abl
typesubtyp
influenza
virus
poc
test
may
avail
detect
novel
respiratori
virus
avian
influenza
virus
novel
influenza
reassort
first
appear
sensit
immunochromatograph
ridt
may
also
reduc
context
newli
circul
avian
influenza
virus
evidenc
influenza
factor
may
reduc
sensit
ridt
includ
type
respiratori
tract
specimen
collect
time
symptom
onset
specimen
collect
poor
specimen
collect
suboptim
specimen
transport
misinterpret
test
result
inexperienc
oper
use
object
reader
interpret
result
may
howev
reduc
latter
countri
public
univers
healthcar
system
australia
patholog
test
done
outsid
nation
associ
test
author
accredit
laboratori
reimburs
contrast
cost
perform
poc
test
born
endus
countri
without
healthcar
system
may
limit
uptak
although
poc
test
deploy
near
patient
test
done
outsid
accredit
laboratori
may
impact
qualiti
perform
test
despit
likelihood
increas
uptak
poc
test
futur
central
refer
laboratori
test
still
requir
detect
respiratori
pathogen
poc
test
neg
avail
character
respiratori
virus
detect
typingsubtyp
influenza
virus
identifi
coinfect
antivir
suscept
test
surveil
inform
public
health
author
impend
current
outbreak
although
accur
diseas
surveil
relev
health
author
may
hamper
use
tradit
standalon
poc
devic
circumv
new
technolog
allow
wireless
data
transfer
direct
public
health
depart
earli
gener
poc
test
membranebas
nonnucl
acid
amplif
antigen
detect
test
influenza
viru
detect
lfic
assay
contain
antibodi
direct
influenza
b
viru
nucleoprotein
conjug
colloid
gold
nitrocellulos
strip
affix
onto
card
cassett
cartridg
viral
antigen
present
sampl
bind
antibodycolloid
gold
conjug
trap
captur
reagent
result
appear
color
band
test
strip
lfic
assay
also
avail
detect
rsv
antigenbas
test
lower
sensit
naatbas
poc
test
reason
perform
pediatr
popul
higher
viral
shed
correspond
higher
viral
load
although
arcdia
intern
turku
finland
multianalyt
system
detect
multipl
respiratori
virus
simultan
includ
influenza
rsv
parainfluenzavirus
human
metapneumoviru
hmpv
bocaviru
coronaviru
adenoviru
requir
special
equip
less
portabl
may
alway
avail
lfic
test
strip
subject
reader
interpret
fluoresc
immunoassay
fia
develop
improv
test
interpret
use
similar
principl
lfic
assay
fia
sofia
influenza
b
quidel
corp
san
diego
ca
veritor
bd
diagnost
spark
md
system
use
fluoresc
reader
optic
colorimetr
devic
detect
influenza
nucleoprotein
respect
sofia
fia
use
specif
antibodyco
bead
coupl
heat
lightstabl
europium
chelat
instead
colloid
gold
lfic
assay
result
read
object
tabl
list
exampl
perform
nonnucl
acid
amplificationbas
poc
test
current
avail
detect
respiratori
virus
although
nucleic
acid
amplificationbas
poc
test
avail
year
uptak
limit
slower
tat
cost
despit
increas
sensit
specif
potenti
influenza
viru
typingsubtyp
compar
nonnucl
acid
amplificationbas
test
tat
min
gener
consid
long
poc
applic
recent
tat
substanti
improv
improv
rtpcr
method
use
loopmedi
isotherm
amplif
low
cycl
threshold
valu
surrog
high
viral
load
howev
interpret
caution
given
nonuniform
sampl
type
volum
exampl
nasal
swab
ns
nose
throat
swab
nt
nasopharyng
swab
np
nasopharyng
aspir
npa
influenza
b
util
isotherm
nucleic
acid
amplif
qualit
detect
influenza
b
virus
assay
involv
realtim
fluorescencebas
detect
short
amplicon
follow
exponenti
isotherm
amplif
unlik
naat
assay
requir
nucleic
acid
extract
follow
thermal
cycl
use
special
equip
assay
perform
use
small
benchtop
instrument
tat
min
system
roch
diagnost
basel
switzerland
contain
reagent
requir
nucleic
acid
extract
rtpcr
amplif
detect
influenza
b
virus
singl
assay
tube
tube
place
benchtop
analyz
size
shoebox
result
avail
within
min
rtpcr
cartridgebas
xpress
flursv
xc
assay
cepheid
inc
sunnyval
ca
usa
also
tat
min
respect
detect
influenza
b
rsv
respiratori
panel
biofir
diagnost
salt
lake
citi
ut
usa
system
detect
virus
bacteria
use
autom
multiplex
pcr
format
perform
nucleic
acid
extract
amplif
bench
top
instrument
although
tat
assay
h
instrument
may
appli
specif
situat
given
rang
pathogen
test
simultan
tabl
detail
type
perform
current
nucleic
acid
amplificationbas
poc
test
use
detect
respiratori
pathogen
perform
poc
test
affect
varieti
factor
includ
respiratori
specimen
type
age
subject
well
qualiti
handl
time
sampl
collect
report
sensit
respiratori
virus
like
detect
specimen
collect
soon
symptom
onset
viral
load
higher
earli
ill
viral
shed
peak
first
h
ill
adult
children
gener
higher
viral
load
prolong
viral
shed
compar
adult
optim
specimen
type
young
children
npa
adult
pair
nt
np
sampl
collect
lower
respiratori
tract
hospit
patient
may
improv
diagnost
yield
gener
poc
test
vrti
perform
upper
respiratori
tract
sampl
includ
nt
np
npa
howev
nucleic
acid
amplificationbas
poc
test
may
perform
lower
respiratori
tract
sampl
tracheal
aspir
bronchoalveolar
lavag
whilst
specimen
gener
test
soon
collect
poc
transport
central
laboratori
test
poc
test
perform
bedsid
clinician
laboratori
train
laboratori
staff
although
poc
platform
rel
simpl
oper
train
sampl
collect
platform
use
essenti
improv
test
perform
recoveri
respiratori
virus
affect
type
transport
media
use
temperatur
specimen
transport
nasopharyng
oropharyng
sampl
detect
enhanc
use
flock
swab
transport
univers
viral
transport
media
promptli
laboratori
compar
dacron
polyest
rayon
swab
shown
flock
swab
compar
sensit
specif
npa
diagnosi
vrti
also
advantag
less
invas
requir
devic
collect
make
wide
access
sputum
prefer
specimen
due
viscos
recent
studi
show
higher
mean
influenza
rsv
hmpv
load
test
sputa
use
diagnost
assay
process
use
dunk
swirl
method
compar
nt
method
involv
dunk
steril
swab
sputum
swirl
swab
steril
water
subsequ
process
addit
wolff
et
al
note
improv
detect
viral
pathogen
test
highqual
sputa
defin
epitheli
cellslow
power
field
white
blood
cellslow
power
field
qualiti
score
compar
nasopharyng
oropharyng
swab
use
array
card
thermo
fischer
scientif
although
saliva
swab
specimen
prefer
detect
respiratori
virus
use
poc
test
previou
evalu
demonstr
compar
detect
rate
compar
np
use
naat
contrast
anoth
studi
show
test
saliva
sampl
improv
detect
respiratori
virus
npa
neg
volum
method
nucleic
acid
extract
submit
specimen
also
affect
naat
perform
differ
method
suit
rna
dna
total
nucleic
acid
commerci
extract
method
respiratori
specimen
type
age
subject
test
also
affect
perform
naat
poc
test
usual
perform
laboratori
subject
qualiti
assur
requir
impos
laboratori
accredit
purpos
test
gener
regist
approv
govern
bodi
us
fda
europ
australia
therapeut
good
administr
howev
manufactur
oblig
monitor
andor
improv
perform
diagnost
assay
may
declin
time
due
antigen
genotyp
diverg
establish
virus
therefor
import
refer
laboratori
continu
assess
perform
poc
test
notifi
relev
manufactur
govern
bodi
declin
perform
detect
sever
guidelin
polici
document
avail
guid
implement
specifi
key
requir
poc
test
intern
standard
iso
poc
test
requir
qualiti
compet
outlin
requir
need
appli
perform
poc
test
intern
qualiti
control
extern
qualiti
assess
requir
ensur
reliabl
result
qualiti
control
materi
avail
patient
specimen
substitut
result
compar
anoth
accredit
laboratori
import
issu
need
consid
includ
preimplement
valid
poc
devic
oversight
clinic
govern
maintain
good
laboratori
practic
oper
devic
greater
awar
respiratori
virus
caus
precipit
upper
lower
respiratori
tract
infect
primari
care
hospit
set
worldwid
respiratori
tract
infect
caus
substanti
morbid
mortal
clinic
present
vrti
similar
laboratori
confirm
import
tradit
test
method
substanti
improv
pathogenspecif
antivir
requir
identif
underli
etiolog
agent
time
fashion
futur
technolog
advanc
doubt
improv
perform
poc
test
data
random
control
trial
await
clinic
financi
impact
poc
test
manag
patient
acut
respiratori
ill
vrti
caus
signific
morbid
mortal
worldwid
similar
clinic
present
make
challeng
identifi
pathogen
respons
without
microbiolog
confirm
increas
avail
therapi
direct
specif
pathogen
host
respons
place
greater
import
make
accur
rapid
diagnosi
manag
vrti
novel
point
care
technolog
facilit
although
near
patient
test
use
individu
patient
manag
sampl
also
refer
diagnost
laboratori
special
test
includ
antivir
resist
test
epidemiolog
purpos
andor
vaccin
develop
indic
increas
pressur
laboratori
aid
diagnosi
vrti
within
clinic
relev
time
frame
benefit
patient
treatment
guid
infect
control
practic
obviat
unnecessari
investig
therapi
improv
public
health
surveil
may
achiev
use
poc
devic
bedsid
resourcerich
poor
set
sever
platform
calibr
selftest
patient
improv
technolog
includ
miniatur
test
platform
advanc
batteri
capac
enhanc
portabl
expans
test
menu
data
transmiss
revolution
poc
test
like
shift
test
away
tradit
central
diagnost
laboratori
clinician
patholog
provid
public
health
profession
prepar
inevit
impend
paradigm
shift
greater
awar
virus
caus
precipit
upper
lower
respiratori
tract
infect
vrti
respons
substanti
morbid
mortal
worldwideth
clinic
present
vrti
often
similar
make
laboratori
confirm
paramount
treatment
individu
also
public
healthalthough
viral
cultur
remain
gold
standard
diagnosi
practic
viru
isol
replac
naat
refer
laboratori
given
increas
sensit
specif
breadth
reduc
tat
pathogen
detectionpointofcar
test
defin
test
patient
sampl
perform
surgeri
clinic
near
time
consultationpointofcar
test
nonmolecular
lfic
fia
molecular
basedth
perform
poc
test
affect
varieti
factor
includ
type
respiratori
sampl
age
subject
well
qualiti
handl
time
sampl
collectionadvantag
poc
test
includ
improv
clinic
decisionmak
qualiti
care
includ
reduct
unnecessari
investig
therapi
prescript
antivir
well
guid
infect
control
practic
reduc
costsdisadvantag
poc
test
includ
reduc
sensit
specif
nonmolecular
base
assay
well
expens
limit
valid
shelf
lifea
develop
assur
criteria
paradigm
poc
test
devic
base
later
flow
immunochromatographi
remain
domin
method
despit
obviou
limit
limit
sensit
inabl
multiplex
